Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 85,700 shares, an increase of 724.0% from the February 13th total of 10,400 shares. Based on an average daily trading volume, of 2,040,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 5.5% of the company’s stock are short sold.

Salarius Pharmaceuticals Stock Performance

Shares of SLRX stock opened at $0.96 on Friday. The stock’s 50-day simple moving average is $1.81 and its 200-day simple moving average is $1.64. The firm has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.12 and a beta of 0.59. Salarius Pharmaceuticals has a fifty-two week low of $0.90 and a fifty-two week high of $7.20.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.